Press Releases

Date Title and Summary View
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten
View HTML
Toggle Summary ZOSANO PHARMA, INC. PRESENTS POSITIVE PHASE 2 RESULTS OF ITS NEEDLE-FREE OSTEOPOROSIS THERAPY
- Rapid Delivery Transdermal Patch Demonstrates Increase in Lumbar Spine and
 Hip Bone Mineral Density -
View HTML
Toggle Summary ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS
ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS Fremont, Calif. – March 31, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical
View HTML
Toggle Summary ZOSANO PHARMA, INC. TO PRESENT AT THE 13TH ANNUAL DRUG DELIVERY PARTNERSHIPS MEETING
- Presentation to Include Update on Two New Pipeline Programs -
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES ZOSANO PHARMA, INC. COMPLETES POSITIVE END-OF-PHASE 2 MEETING WITH FDA REGARDING ZP- PTH PATCH FOR OSTEOPOROSIS
ZOSANO PHARMA, INC. ANNOUNCES ZOSANO PHARMA, INC. COMPLETES POSITIVE END-OF-PHASE 2 MEETING WITH FDA REGARDING ZP- PTH PATCH FOR OSTEOPOROSIS Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal
View HTML
Toggle Summary Zosano Pharma, Inc. Completes Positive End-Of-Phase 2 Meeting With Fda Regarding ZP- PTH Patch.
Zosano Pharma, Inc. Completes Positive End-Of-Phase 2 Meeting With Fda Regarding ZP- PTH Patch. Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that it
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 OSTEOPOROSIS STUDY
ZP-PTH Patch Demonstrates Increase in Lumbar Spine and Hip Bone Mineral Density
View HTML
Toggle Summary ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM
ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 TRIAL WITH PTH TRANSDERMAL PATCH IN OSTEOPOROSIS
DATA TO BE PRESENTED AT ACR SCIENTIFIC MEETING
View HTML